Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis

Validation of Treatment Decision Algorithms for Childhood Tuberculosis at District Health Care Levels in Mozambique and Zambia - the Decide-TB Cluster-randomized Pragmatic Trial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The Decide-TB project aims to generate evidence for the implementation of a comprehensive Treatment Decision Algorithms (TDA) based approach for TB in children living in high TB burden and resource-limited countries, at District Hospital (DH) and Primary Health Centre (PHC) levels, and to facilitate the integration of this evidence within practices and policies. This programmatic pilot led by the National TB Programs (NTP) will test a TDA-based approach integrating TB screening, diagnosis, treatment decision-making, and disease severity assessment for shorter treatment eligibility, for use at a lower level of healthcare. This TDA-based approach will be evaluated in a hybrid effectiveness implementation study based on a pragmatic stepped wedge cluster-randomized trial. The Decide TB project will be implemented at the district level, targeting five districts in each country. Each cluster in a district will be made up of one district hospital and six primary health centers. The study will develop a Clinical Decision Support System (CDSS) to operationalize the use of TDAs, and strengthen District Health Information Systems (DHIS2) to collect individual data, which will contribute to monitoring and evaluation, clinical mentoring, and supervision by the country's NTPs.

Who May Be Eligible (Plain English)

Who May Qualify: The effectiveness assessment will be conducted using aggregated or individual data from direct beneficiaries of the intervention: - All sick children aged below 15 years entering the selected health facilities (DH and PHC) at either outpatient (OPD) or inpatient (IPD) departments, including children from high-risk groups, as well as children identified as contact of TB cases through community- or facility-based household contact tracing. - Children with presumptive TB. The WHO definition of presumptive TB will be used, as defined in the 2022 WHO Operational Handbook, namely: children are classified as having presumptive TB if they have unremitting symptoms lasting more than 2 weeks (any one of cough, fever, not eating well or anorexia, weight loss or failure to thrive, fatigue, reduced playfulness or decreased activity) . The definitions of presumptive TB have been adapted locally for the programmatic pilot. All children with presumptive TB as defined locally will be considered in the intervention and in secondary effectiveness and sub-group analyses. High-risk group will be defined using the definition in WHO-suggested TDAs A\&B as children younger than 2 years, CLHIV or children with SAM. CLHIV will be defined per national testing strategy including positive PCR test for children below the age of 18 months. Children will be considered to have SAM (and thereby be eligible for the TB-Speed SAM algorithm) using WHO criteria. These include being \<5 years with a weight-for-height Z score (WHZ) \< -3 SDs or mid-upper arm circumference (MUAC) \< 115 mm (in children over 6 months) or clinical signs of bilateral pitting oedema, and being aged ≥5 years with a body mass index (BMI) for age Z-score \< -3SD. Who Should NOT Join This Trial: There will be no exclusion criteria for the programmatic pilot: all children will be offered the intervention. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: The effectiveness assessment will be conducted using aggregated or individual data from direct beneficiaries of the intervention: * All sick children aged below 15 years entering the selected health facilities (DH and PHC) at either outpatient (OPD) or inpatient (IPD) departments, including children from high-risk groups, as well as children identified as contact of TB cases through community- or facility-based household contact tracing. * Children with presumptive TB. The WHO definition of presumptive TB will be used, as defined in the 2022 WHO Operational Handbook, namely: children are classified as having presumptive TB if they have unremitting symptoms lasting more than 2 weeks (any one of cough, fever, not eating well or anorexia, weight loss or failure to thrive, fatigue, reduced playfulness or decreased activity) . The definitions of presumptive TB have been adapted locally for the programmatic pilot. All children with presumptive TB as defined locally will be considered in the intervention and in secondary effectiveness and sub-group analyses. High-risk group will be defined using the definition in WHO-suggested TDAs A\&B as children younger than 2 years, CLHIV or children with SAM. CLHIV will be defined per national testing strategy including positive PCR test for children below the age of 18 months. Children will be considered to have SAM (and thereby be eligible for the TB-Speed SAM algorithm) using WHO criteria. These include being \<5 years with a weight-for-height Z score (WHZ) \< -3 SDs or mid-upper arm circumference (MUAC) \< 115 mm (in children over 6 months) or clinical signs of bilateral pitting oedema, and being aged ≥5 years with a body mass index (BMI) for age Z-score \< -3SD. Exclusion Criteria: There will be no exclusion criteria for the programmatic pilot: all children will be offered the intervention.

Treatments Being Tested

OTHER

The comprehensive TDA based approach

The intervention consists of implementing a comprehensive TDA-based approach for TB diagnosis and treatment decision-making, including shorter treatment for non-severe TB in children identified as TB presumptive cases through a CDSS. It will also include the management of high-risk groups. In practice, all sick children will be assessed using the WHO-suggested TDAs A with CXR (DH) and B without CXR (PHC). CLHIV and those hospitalised with SAM at DH will have further assessment and treatment decisions based on the PAANTHER and TB-Speed SAM TDAs, respectively. Clinical and microbiological assessment data will be incorporated into a CDSS to help with the clinical decision to initiate TB treatment. The CDSS will incorporate specific features and test results for high-risk group children based on the PAANTHER TDA and the TB-Speed SAM TDA and will incorporate the results of the severity assessment to guide the choice of TB treatment duration once children are diagnosed with TB.

Locations (20)

Chawama Urban Health Centre
Chingola, Copperbelt, Zambia
Chiwempala Urban Health Centre
Chingola, Copperbelt, Zambia
Kabundi East Urban Health Clinic
Chingola, Copperbelt, Zambia
Kasompe Urban Health Centre
Chingola, Copperbelt, Zambia
Muchinshi Rural Health Centre
Chingola, Copperbelt, Zambia
Nchanga 1 Urban Health Centre
Chingola, Copperbelt, Zambia
Nchanga North Referal Hospital
Chingola, Copperbelt, Zambia
Allessandras Urban Health Centre
Luanshya, Copperbelt, Zambia
Chaisa Urban Health Centre
Luanshya, Copperbelt, Zambia
Fisenge Urban Health Centre
Luanshya, Copperbelt, Zambia
Kawama Urban Health Centre
Luanshya, Copperbelt, Zambia
Malaika Urban Health Centre
Luanshya, Copperbelt, Zambia
Mikomfwa Urban Health Centre
Luanshya, Copperbelt, Zambia
Roan Antelope General Hospital
Luanshya, Copperbelt, Zambia
Thomson District Hospital
Luanshya, Copperbelt, Zambia
Chipepo Rural Health Centre
Chirundu, Southern Province, Zambia
Hachipilika Rural Health Centre
Chirundu, Southern Province, Zambia
Jamba Rural Health Centre
Chirundu, Southern Province, Zambia
Kapululira Rural Health Centre
Chirundu, Southern Province, Zambia
Lusitu Rural Health Centre
Chirundu, Southern Province, Zambia